| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jul 26, 2017 | SVP, GM - Oncology | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 12,818 | -- | 12,818 | |
| Jul 26, 2017 | SVP, GM - Oncology | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 7,296 | -- | 7,296 | |
| Jul 26, 2017 | SVP/GM, Global Vascular | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 3,739 | -- | 13,739 | |
| Jul 26, 2017 | SVP/GM, Global Vascular | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 13,137 | -- | 13,137 | |
| Jul 26, 2017 | SVP/GM, Global Vascular | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 7,477 | -- | 7,477 | |
| Jul 26, 2017 | SVP and General Counsel | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 3,705 | -- | 34,947 | |
| Jul 26, 2017 | SVP and General Counsel | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 13,018 | -- | 13,018 | |
| Jul 26, 2017 | SVP and General Counsel | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 7,409 | -- | 7,409 | |
| Jul 25, 2017 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 14,000 | $15.75 | 66,037 | |
| Jul 25, 2017 | Director | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 12,879 | $17.12 | 53,158 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.